Clinical trial
ZD6474 in Treating Patients With Small Cell Lung Cancer
NCT00066313 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00066313 |
|---|---|
| Title | ZD6474 in Treating Patients With Small Cell Lung Cancer |
| Official title | A Phase II Study Of ZD6474 Or Placebo In Small Cell Lung Cancer Patients Who Have Complete Or Partial Response To Induction Chemotherapy +/- Radiation Therapy |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug, Procedure |
| Interventions | vandetanib, adjuvant therapy |
| Start date | May 1, 2003 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Aug 7, 2003 |
| Last update posted | Aug 24, 2016 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: